Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

At close: 24 January at 2:06:50 pm GMT-3 ...

Shares of CRISPR Therapeutics have lost nearly 34% in the past year compared with the industry’s 14% decline, as seen in the chart below. Shares of the company are also currently trading below ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

After hours: 31 January at 7:56:28 pm GMT-5 ...

As of 11:10:38 a.m. GMT-3. Market Open.